Javascript must be enabled to continue!
Evidence for Genes in Addition to Tlr7 in the Yaa Translocation Linked with Acceleration of Systemic Lupus Erythematosus
View through CrossRef
Abstract
The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration). Recently, the Yaa mutation was identified to be a translocation from the telomeric end of the X chromosome (containing the gene encoding TLR7) onto the Y chromosome. In the present study, we determined whether the Tlr7 gene duplication is indeed responsible for the Yaa-mediated acceleration of SLE. Analysis of C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus (B6.Nba2) bearing the Yaa mutation revealed that introduction of the Tlr7 null mutation on the X chromosome significantly reduced serum levels of IgG autoantibodies against DNA and ribonucleoproteins, as well as the incidence of lupus nephritis. However, the protection was not complete, because these mice still developed high titers of anti-chromatin autoantibodies and retroviral gp70-anti-gp70 immune complexes, and severe lupus nephritis, which was not the case in male B6.Nba2 mice lacking the Yaa mutation. Moreover, we found that the Tlr7 gene duplication contributed to the development of monocytosis, but not to the reduction of marginal zone B cells, which both are cellular abnormalities causally linked to the Yaa mutation. Our results indicate that the Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome.
Oxford University Press (OUP)
Title: Evidence for Genes in Addition to Tlr7 in the Yaa Translocation Linked with Acceleration of Systemic Lupus Erythematosus
Description:
Abstract
The accelerated development of systemic lupus erythematosus (SLE) in male BXSB mice is associated with the genetic abnormality in its Y chromosome, designated Yaa (Y-linked autoimmune acceleration).
Recently, the Yaa mutation was identified to be a translocation from the telomeric end of the X chromosome (containing the gene encoding TLR7) onto the Y chromosome.
In the present study, we determined whether the Tlr7 gene duplication is indeed responsible for the Yaa-mediated acceleration of SLE.
Analysis of C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus (B6.
Nba2) bearing the Yaa mutation revealed that introduction of the Tlr7 null mutation on the X chromosome significantly reduced serum levels of IgG autoantibodies against DNA and ribonucleoproteins, as well as the incidence of lupus nephritis.
However, the protection was not complete, because these mice still developed high titers of anti-chromatin autoantibodies and retroviral gp70-anti-gp70 immune complexes, and severe lupus nephritis, which was not the case in male B6.
Nba2 mice lacking the Yaa mutation.
Moreover, we found that the Tlr7 gene duplication contributed to the development of monocytosis, but not to the reduction of marginal zone B cells, which both are cellular abnormalities causally linked to the Yaa mutation.
Our results indicate that the Yaa-mediated acceleration of SLE as well as various Yaa-linked cellular traits cannot be explained by the Tlr7 gene duplication alone, and suggest additional contributions from other duplicated genes in the translocated X chromosome.
Related Results
Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
ABSTRACTBackgroundAs a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanis...
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus erythematosus) and non-s...
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
The impaired suppressive function of regulatory T cells is well-understood in systemic lupus erythematosus. This is likely due to changes in Foxp3 expression that are crucial for r...
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
AbstractAlthough glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response...
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
Systemic Lupus Erythematosus is an autoimmune multisystem pathology, characterized by being more prevalent in women, especially African women. One of the most frequent pathologies ...
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement, generating chronic inflammation and damage of more than one organ. I...
ADP-ribosylation factor-like 8b is required for the development of mouse models of systemic lupus erythematosus
ADP-ribosylation factor-like 8b is required for the development of mouse models of systemic lupus erythematosus
Abstract
Toll-like receptor 7 (TLR7) and type I interferons (IFN-1) are essential for the development of systemic lupus erythematosus (SLE) models such as BXSB.Yaa a...
Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review
Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review
Systemic lupus erythematosus (SLE) is an autoimmunemulti-systemic disease; it is a controlled disease but isnot curable. SLE affects different systems in the body,such as cardiac, ...

